Academic Journal
View in EDS
HTML Full Text

Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.

Bibliographic Details
Title: Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
Authors: Short, Nicholas J.1 (AUTHOR) nshort@mdanderson.org, Kantarjian, Hagop1 (AUTHOR), Jabbour, Elias1 (AUTHOR)
Source: Leukemia & Lymphoma. Oct2024, Vol. 65 Issue 10, p1405-1417. 13p.
Subject Terms: *HEMATOPOIETIC stem cell transplantation, *PHILADELPHIA chromosome, *LYMPHOBLASTIC leukemia, *OLDER people, *ACUTE leukemia
Abstract: Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional chemotherapy in this setting. Several prospective clinical trials have explored the use of these agents in adults with newly diagnosed B-cell ALL, with promising outcomes observed in younger and older adults and in both Philadelphia chromosome (Ph)-positive and Ph-negative ALL. These novel regimens result in high rates of deep measurable residual disease (MRD) negativity and may improve survival compared with chemotherapy-only approaches, allowing for less reliance on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). This review discusses novel approaches to integrating INO and/or blinatumomab into frontline ALL regimens, including the potential role of chemotherapy-free regimens in some subgroups. The role of MRD monitoring is also discussed, including how this can inform decisions for consolidative allogeneic HSCT or investigational approaches with CD19 CAR T-cells. [ABSTRACT FROM AUTHOR]
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=10428194&ISBN=&volume=65&issue=10&date=20241001&spage=1405&pages=1405-1417&title=Leukemia & Lymphoma&atitle=Advances%20in%20the%20treatment%20of%20adults%20with%20newly%20diagnosed%20B-cell%20acute%20lymphoblastic%20leukemia%3A%20the%20role%20of%20frontline%20immunotherapy-based%20regimens.&aulast=Short%2C%20Nicholas%20J.&id=DOI:10.1080/10428194.2024.2364043
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: a9h
DbLabel: Academic Search Complete
An: 180040902
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Short%2C+Nicholas+J%2E%22">Short, Nicholas J.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> nshort@mdanderson.org</i><br /><searchLink fieldCode="AR" term="%22Kantarjian%2C+Hagop%22">Kantarjian, Hagop</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jabbour%2C+Elias%22">Jabbour, Elias</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Leukemia+%26+Lymphoma%22">Leukemia & Lymphoma</searchLink>. Oct2024, Vol. 65 Issue 10, p1405-1417. 13p.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22HEMATOPOIETIC+stem+cell+transplantation%22">HEMATOPOIETIC stem cell transplantation</searchLink><br />*<searchLink fieldCode="DE" term="%22PHILADELPHIA+chromosome%22">PHILADELPHIA chromosome</searchLink><br />*<searchLink fieldCode="DE" term="%22LYMPHOBLASTIC+leukemia%22">LYMPHOBLASTIC leukemia</searchLink><br />*<searchLink fieldCode="DE" term="%22OLDER+people%22">OLDER people</searchLink><br />*<searchLink fieldCode="DE" term="%22ACUTE+leukemia%22">ACUTE leukemia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional chemotherapy in this setting. Several prospective clinical trials have explored the use of these agents in adults with newly diagnosed B-cell ALL, with promising outcomes observed in younger and older adults and in both Philadelphia chromosome (Ph)-positive and Ph-negative ALL. These novel regimens result in high rates of deep measurable residual disease (MRD) negativity and may improve survival compared with chemotherapy-only approaches, allowing for less reliance on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). This review discusses novel approaches to integrating INO and/or blinatumomab into frontline ALL regimens, including the potential role of chemotherapy-free regimens in some subgroups. The role of MRD monitoring is also discussed, including how this can inform decisions for consolidative allogeneic HSCT or investigational approaches with CD19 CAR T-cells. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=180040902
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2024.2364043
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 13
        StartPage: 1405
    Subjects:
      – SubjectFull: HEMATOPOIETIC stem cell transplantation
        Type: general
      – SubjectFull: PHILADELPHIA chromosome
        Type: general
      – SubjectFull: LYMPHOBLASTIC leukemia
        Type: general
      – SubjectFull: OLDER people
        Type: general
      – SubjectFull: ACUTE leukemia
        Type: general
    Titles:
      – TitleFull: Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Short, Nicholas J.
      – PersonEntity:
          Name:
            NameFull: Kantarjian, Hagop
      – PersonEntity:
          Name:
            NameFull: Jabbour, Elias
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 10428194
          Numbering:
            – Type: volume
              Value: 65
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Leukemia & Lymphoma
              Type: main
ResultId 1